Guangzhou Zhongyi Of China Sees Sales In GSK Avandia Problems
This article was originally published in PharmAsia News
Executive Summary
China's Guangzhou Zhongyi Pharmaceutical expects its Xiaoke diabetes drug to gain sales as a result of GlaxoSmithKline's safety problems with its Avandia (rosiglitazone)